Medicine & Life Sciences
Denosumab
100%
Osteoporotic Fractures
84%
National Institutes of Health (U.S.)
73%
Technology
46%
Costs and Cost Analysis
17%
Zoledronic Acid
14%
Quality-Adjusted Life Years
12%
Diphosphonates
12%
Hip Fractures
11%
Primary Prevention
11%
Cost-Benefit Analysis
9%
strontium ranelate
8%
Ibandronic Acid
8%
Teriparatide
7%
Placebos
7%
Raloxifene Hydrochloride
7%
Biomedical Technology Assessment
6%
Secondary Care
6%
Drug Costs
6%
Drug Monitoring
6%
Therapeutics
6%
Subcutaneous Injections
5%
Nursing Homes
5%
Contraindications
5%
General Practice
5%
Secondary Prevention
5%
Incidence
5%
Wrist
5%
Randomized Controlled Trials
3%
Weights and Measures
3%
Social Sciences
costs
40%
health
32%
evidence
29%
Group
18%
incidence
15%
need for care
12%
willingness to pay
11%
technology assessment
10%
quality good
10%
nursing home
9%
tolerance
8%
monitoring
6%
drug
6%
instruction
5%
methodology
4%
time
3%